Trial Profile
A study to assess the safety and efficacy of tenofovir disoproxil fumarate (TDF) substitution for HBIg in liver transplantation patients receiving long-term low dose IM HBIg / lamivudine (LAM) prophylaxis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 08 Dec 2011 New trial record